Larotaxel

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Larotaxel (XRP9881) 是一种紫杉烷类似物，具有抗紫杉烷抗性乳腺癌的临床前活性。Larotaxel (XRP9881) 通过促进微管蛋白装配和稳定微管发挥其细胞毒性作用，并最终通过细胞凋亡导致细胞死亡。Larotaxel (XRP9881) 具有穿越血脑屏障的能力，对 P-糖蛋白 1 的亲和力比 Docetaxel 低得多。

Larotaxel (XRP9881) is a taxane analogue with preclinical activity against taxane-resistant breast cancer. Larotaxel (XRP9881) exerts its cytotoxic effect by promoting tubulin assembly and stabilizing microtubules, ultimately leading to cell death by apoptosis. It presents the ability to cross the blood brain barrier and has a much lower affinity for P-glycoprotein 1 than Docetaxel.

——

——

——

Others

Other Targets

P-gp

——

——

156294-36-9

831.9

C45H53NO14

>98% (HPLC)

In Vitro:?DMSO 中的溶解度 : ≥ 50 mg/mL (60.10 mM)

[H][C@@]12C[C@@H]3C[C@@]33C(=O)[C@]([H])(OC(C)=O)C4=C(C)[C@@H](C[C@@](O)([C@@H](OC(=O)c5ccccc5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c1ccccc1

——

(-20℃)

With Ice Pack

≥ 2 years